Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2010

Open Access 01-12-2010 | Research

Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence

Authors: Wenjie Sun, Cheng N Leong, Zhen Zhang, Jiade J Lu

Published in: Radiation Oncology | Issue 1/2010

Login to get access

Abstract

Background

Radiation therapy is an important cancer treatment modality in both adjuvant and definitive setting, however, the use of radiation therapy for elective treatment of regional lymph nodes is controversial for pancreatic cancer. No consensus on proper selection and delineation of subclinical lymph nodal areas in adjuvant or definitive radiation therapy has been suggested either conclusively or proposed for further investigation. This analysis aims to study the pattern of lymph node metastasis through a pooled analysis of published results after radical tumor and lymph nodal resection with histological study in pancreatic cancer.

Methods

Literature search using electronic databases including MEDLINE, EMBASE, and CANCERLIT from January 1970 to June 2009 was performed, supplemented by review of references. Eighteen original researches and a total of 5954 pancreatic cancer patients underwent radical surgical resection were included in this analysis. The probability of metastasis in regional lymph nodal stations (using Japan Pancreas Society [JPS] Classification) was calculated and analyzed based on the location and other characteristics of the primary disease.

Results

Commonly involved nodal regions in patients with pancreatic head tumor include lymph nodes around the common hepatic artery (Group 8, 9.79%), posterior pancreaticoduodenal lymph nodes (Group 13, 32.31%), lymph nodes around the superior mesenteric artery (Group 14, 15.85%), paraaortic lymph nodes (Group 16, 10.92%), and anterior pancreaticoduodenal lymph nodes (Group 17, 19.78%); The probability of metastasis in other lymph nodal regions were <9%.
Commonly involved nodal regions in patients with pancreatic body/tail tumor include lymph nodes around the common hepatic artery (Group 8, 15.07%), lymph nodes around the celiac trunk (Group 9, 9.59%), lymph nodes along the splenic artery (Group 11, 35.62%), lymph nodes around the superior mesenteric artery (Group 14, 9.59%), paraaortic lymph nodes (Group 16, 16.44%), and inferior body lymph nodes (Group 18, 24.66%). The probability of metastasis in other lymph nodal regions were <9%.

Conclusions

Pancreatic cancer has a high propensity of regional lymphatic metastases; however, clear patterns including the site and probability of metastasis can be identified and used as a guide of treatment in patients with resectable pancreatic cancer. Further clinical investigation is needed to study the efficacy of elective treatment to CTV defined based on these patterns using high-dose conformal or intensity-modulated radiation therapy.
Appendix
Available only for authorised users
Literature
1.
Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 2004, 28: 219-230. 10.1097/00006676-200404000-00002CrossRefPubMed
2.
Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, Evans RG: Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990, 66: 56-61. 10.1002/1097-0142(19900701)66:1<56::AID-CNCR2820660112>3.0.CO;2-6CrossRefPubMed
3.
Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD: Resected adenocarcinoma of the pancreas--616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000, 4: 567-579. 10.1016/S1091-255X(00)80105-5CrossRefPubMed
4.
Nitecki SS, Sarr MG, Colby TV, van Heerden JA: Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995, 221: 59-66. 10.1097/00000658-199501000-00007PubMedCentralCrossRefPubMed
5.
Kalser MH, Ellenberg SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120: 899-903.CrossRefPubMed
6.
Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230: 776-782. 10.1097/00000658-199912000-00006PubMedCentralCrossRefPubMed
7.
Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB: Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology group Study. J Clin Oncol 1998, 16: 317-323.PubMed
8.
Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO Jr, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981, 48: 1705-1710. 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4CrossRefPubMed
9.
Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988, 80: 751-755. 10.1093/jnci/80.10.751CrossRef
10.
Chmura SJ, Heimann R: Normal tissue toxicity using intensity modulated radiation therapy(IMRT) in pancreatic cancer and cholangiocarcinoma. [Abstract] Proc Am Soc Clin Oncol 2001, 20: 1093.
11.
Spalding AC, Jee KW, Vineberg K, Jablonowski M, Fraass BA, Pan CC, Lawrence TS, Haken RK, Ben-Josef E: Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys 2007, 34: 521-529. 10.1118/1.2426403CrossRefPubMed
12.
Brown MW, Ning H, Arora B, Albert PS, Poggi M, Camphausen K, Citrin D: A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys 2006, 65: 274-283.CrossRefPubMed
13.
Wieland P, Dobler B, Mai S, Hermann B, Tiefenbacher U, Steil V, Wenz F, Lohr F: IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach. Int J Radiat Oncol Biol Phys 2004, 59: 1236-1244. 10.1016/j.ijrobp.2004.02.051CrossRefPubMed
14.
Japan Pancreas Society: Classification of pancreatic carcinoma. 2nd English edition. Tokyo: Kanehara; 2003.
15.
Ishikawa O, Ohhigashi H, Sasaki Y, Kabuto T, Fukuda I, Furukawa H, Imaoka S, Iwanaga T: Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 1988, 208: 215-220. 10.1097/00000658-198808000-00014PubMedCentralCrossRefPubMed
16.
Brunner TB, Merkel S, Grabenbauer GG, Meyer T, Baum U, Papadopoulos T, Sauer R, Hohenberger W: Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis. Int J Radiat Oncol Biol Phys 2005, 62: 1021-1029.CrossRefPubMed
17.
Kayahara M, Nagakawa T, Ohta T, Kitagawa H, Ueno K, Tajima H, Elnemr A, Miwa K: Analysis of paraaortic lymph node involvement in pancreatic carcinoma: a significant indication for surgery? Cancer 1999, 85: 583-590. 10.1002/(SICI)1097-0142(19990201)85:3<583::AID-CNCR8>3.0.CO;2-JCrossRefPubMed
18.
Sierzega M, Popiela T, Kulig J, Nowak K: The ratio of metastatic/resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic head cancer. Pancreas 2006, 33: 240-245. 10.1097/01.mpa.0000235306.96486.2aCrossRefPubMed
19.
Nagakawa T, Kobayashi H, Ueno K, Ohta T, Kayahara M, Mori K, Nakano T, Takeda T, Konishi I, Miyazaki I: The pattern of lymph node involvement in carcinoma of the head of the pancreas. A histologic study of the surgical findings in patients undergoing extensive nodal dissections. Int J Pancreatol 1993, 13: 15-22.PubMed
20.
Nagakawa T, Kobayashi H, Ueno K, Ohta T, Kayahara M, Miyazaki I: Clinical study of lymphatic flow to the paraaortic lymph nodes in carcinoma of the head of the pancreas. Cancer 1994, 73: 1155-1162. 10.1002/1097-0142(19940215)73:4<1155::AID-CNCR2820730406>3.0.CO;2-HCrossRefPubMed
21.
Capussotti L, Massucco P, Ribero D, Viganò L, Muratore A, Calgaro M: Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy. Arch Surg 2003, 138: 1316-1322. 10.1001/archsurg.138.12.1316CrossRefPubMed
22.
Cubilla AL, Fortner J, Fitzgerald PJ: Lymph node involvement in carcinoma of the head of the pancreas area. Cancer 1978, 41: 880-887. 10.1002/1097-0142(197803)41:3<880::AID-CNCR2820410315>3.0.CO;2-JCrossRefPubMed
23.
Nakao A, Harada A, Nonami T, Kaneko T, Nomoto S, Koyama H, Kanazumi N, Nakashima N, Takagi H: Lymph node metastasis in carcinoma of the body and tail of the pancreas. Br J Surg 1997, 84: 1090-1092. 10.1002/bjs.1800840813CrossRefPubMed
24.
Nagai H, Kuroda A, Morioka Y: Lymphatic and local spread of T1 and T2 pancreatic cancer. A study of autopsy material. Ann Surg 1986, 204: 65-71. 10.1097/00000658-198607000-00009PubMedCentralCrossRefPubMed
25.
Kayahara M, Nagakawa T, Futagami F, Kitagawa H, Ohta T, Miyazaki I: Lymphatic flow and neural plexus invasion associated with carcinoma of the body and tail of the pancreas. Cancer 1996, 78: 2485-2491. 10.1002/(SICI)1097-0142(19961215)78:12<2485::AID-CNCR6>3.0.CO;2-JCrossRefPubMed
26.
Kayahara M, Nagakawa T, Kobayashi H, Mori K, Nakano T, Kadoya N, Ohta T, Ueno K, Miyazaki I: Lymphatic flow in carcinoma of the head of the pancreas. Cancer 1992, 70: 2061-2066. 10.1002/1097-0142(19921015)70:8<2061::AID-CNCR2820700808>3.0.CO;2-VCrossRefPubMed
27.
Yoshida T, Matsumoto T, Sasaki A, Shibata K, Aramaki M, Kitano S: Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma. Am J Surg 2004, 187: 736-740. 10.1016/j.amjsurg.2003.07.031CrossRefPubMed
28.
Sakai M, Nakao A, Kaneko T, Takeda S, Inoue S, Kodera Y, Nomoto S, Kanazumi N, Sugimoto H: Para-aortic lymph node metastasis in carcinoma of the head of the pancreas. Surgery 2005, 137: 606-611. 10.1016/j.surg.2005.02.009CrossRefPubMed
29.
Gerdes B, Ramaswamy A, Bartsch DK, Rothmund M: Peripyloric lymph node metastasis is a rare condition in carcinoma of the pancreatic head. Pancreas 2005, 31: 88-92. 10.1097/01.mpa.0000168221.97967.98CrossRefPubMed
30.
Ishikawa O, Ohigashi H, Sasaki Y, Kabuto T, Furukawa H, Nakamori S, Imaoka S, Iwanaga T, Kasugai T: Practical grouping of positive lymph nodes in pancreatic head cancer treated by an extended pancreatectomy. Surgery 1997, 121: 244-249. 10.1016/S0039-6060(97)90352-4CrossRefPubMed
31.
Kayahara M, Nagakawa T, Ueno K, Ohta T, Tsukioka Y, Miyazaki I: Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasion. Surgery 1995, 117: 616-623. 10.1016/S0039-6060(95)80003-4CrossRefPubMed
32.
Kocher HM, Sohail M, Benjamin IS, Patel AG: Technical limitations of lymph node mapping in pancreatic cancer. Eur J Surg Oncol 2007, 33: 887-891.CrossRefPubMed
33.
34.
Withers HR, Peters LJ, Taylor JM: Dose-response relationship for radiation therapy of subclinical disease. Int J Radiat Oncol Biol Phys 1995, 31: 353-359.CrossRefPubMed
35.
Willett CG, Clark JW: Update on combined-modality treatment options for pancreatic cancer. Oncology 2003, 17: 29-36.PubMed
36.
Lemke AJ, Niehues SM, Hosten N, Amthauer H, Boehmig M, Stroszczynski C, Rohlfing T, Rosewicz S, Felix R: Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions--a prospective study with 104 patients. J Nucl Med 2004, 45: 1279-1286.PubMed
37.
De Gaetano AM, Vecchioli A, Minordi LM, Parrella A, Gaudino S, Masselli G, Savino G: Role of diagnostic imaging in abdominal lymphadenopathy. Rays 2000, 25: 463-484.PubMed
38.
Hanbidge AE: Cancer of the pancreas: the best image for early detection--CT, MRI, PET or US? Can J Gastroenterol 2002, 16: 101-105.PubMed
39.
Yu H, Caldwell C, Mah K, Poon I, Balogh J, MacKenzie R, Khaouam N, Tirona R: Automated radiation targeting in head-and-neck cancer using region-based texture analysis of PET and CT images. Int J Radiat Oncol Biol Phys 2009, 75: 618-625.CrossRefPubMed
40.
Geets X, Lee JA, Castadot P, Bol A, Grégoire V: Potential place of FDG-PET for the GTV delineation in head and neck and lung cancers. Cancer Radiother 2009, 13: 594-599.CrossRefPubMed
41.
Yu J, Li X, Xing L, Mu D, Fu Z, Sun X, Sun X, Yang G, Zhang B, Sun X, Ling CC: Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study. Int J Radiat Oncol Biol Phys 2009, 75: 1468-1474.CrossRefPubMed
42.
Strobel K, Heinrich S, Bhure U, Soyka J, Veit-Haibach P, Pestalozzi BC, Clavien PA, Hany TF: Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med 2008, 49: 1408-1413. 10.2967/jnumed.108.051466CrossRefPubMed
43.
Sendler A, Avril N, Helmberger H, Stollfuss J, Weber W, Bengel F, Schwaiger M, Roder JD, Siewert JR: Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 2000, 24: 1121-1129. 10.1007/s002680010182CrossRefPubMed
44.
Kitajima K, Murakami K, Yamasaki E, Kaji Y, Shimoda M, Kubota K, Suganuma N, Sugimura K: Performance of Integrated FDG-PET/Contrast-enhanced CT in the Diagnosis of Recurrent Pancreatic Cancer: Comparison with Integrated FDG-PET/Non-contrast-enhanced CT and Enhanced CT. Mol Imaging Biol 2009, in press.
45.
Manabe T, Ohshio G, Baba N, Miyashita T, Asano N, Tamura K, Yamaki K, Nonaka A, Tobe T: Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer 1989, 64: 1132-1137. 10.1002/1097-0142(19890901)64:5<1132::AID-CNCR2820640528>3.0.CO;2-VCrossRefPubMed
46.
Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Klöppel G, Dhaene K, Michelassi F: Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas. Ann Surg 1998, 228: 508-517. 10.1097/00000658-199810000-00007PubMedCentralCrossRefPubMed
47.
Yeo CJ, Cameron JL, Sohn TA, Coleman J, Sauter PK, Hruban RH, Pitt HA, Lillemoe KD: Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Comparison of morbidity and mortality and short-term outcome. Ann Surg 1999, 229: 613-624. 10.1097/00000658-199905000-00003PubMedCentralCrossRefPubMed
48.
Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, Foster N, Sargent DJ: Pancreas Cancer Working Group: A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005, 138: 618-630. 10.1016/j.surg.2005.06.044CrossRefPubMed
49.
Yoshida T, Matsumoto T, Sasaki A, Shibata K, Aramaki M, Kitano S: Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma. Am J Surg 2004, 187: 736-740. 10.1016/j.amjsurg.2003.07.031CrossRefPubMed
50.
Bussels B, Goethals L, Feron M, Bielen D, Dymarkowski S, Suetens P, Haustermans K: Respiration-induced movement of the upper abdominal organs: A pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer. Radiother Oncol 2003, 68: 69-74. 10.1016/S0167-8140(03)00133-6CrossRefPubMed
51.
Crane CH, Wolff RA, Abbruzzese JL, Evans DB, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Lahoti S, Vauthey JN, Janjan NA: Combining gemcitabine with radiation in pancreatic cancer: Understanding important variables influencing the therapeutic index. Semin Oncol 2001,28(3 Suppl 10):25-33. 10.1053/sonc.2001.22536CrossRefPubMed
52.
Brunner TB, Grabenbauer GG, Klein P, Baum U, Papadopoulos T, Bautz W, Hohenberger W, Sauer R: Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003, 55: 144-153. 10.1016/S0360-3016(02)03818-XCrossRefPubMed
53.
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15: 2403-2413.PubMed
54.
Bai YR, Wu GH, Guo WJ, Wu XD, Yao Y, Chen Y, Zhou RH, Lu DQ: Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study. World J Gastroenterol 2003, 9: 2561-2564.CrossRefPubMed
55.
Ben-Josef E, Shields AF, Vaishampayan U, Vaitkevicius V, El-Rayes BF, McDermott P, Burmeister J, Bossenberger T, Philip PA: Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 2004, 59: 454-459.CrossRefPubMed
Metadata
Title
Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence
Authors
Wenjie Sun
Cheng N Leong
Zhen Zhang
Jiade J Lu
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2010
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-5-28

Other articles of this Issue 1/2010

Radiation Oncology 1/2010 Go to the issue

Case report

Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature

Short report

Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma

Research

Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients

Research

Consequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study

Research

Clinical application of tumor volume in advanced nasopharyngeal carcinoma to predict outcome

Research

Intensity-Modulated Radiotherapy in Patients with Cervical Cancer. An intra-individual Comparison of Prone and Supine Positioning